Hoe verhoudt KVUE's PE Ratio zich tot zijn concurrenten?

KVUE is good value based on its Price-To-Earnings Ratio (38.9x) compared to the peer average (72.4x).

Hoe verhoudt KVUE's PE Ratio zich tot andere bedrijven in de US Personal Products industrie?

KVUE is expensive based on its Price-To-Earnings Ratio (38.9x) compared to the North American Personal Products industry average (24.9x).

Wat is KVUE's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

KVUE is expensive based on its Price-To-Earnings Ratio (38.9x) compared to the estimated Fair Price-To-Earnings Ratio (37.9x).

Wat is de reële prijs van KVUE als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

KVUE ($22.73) is trading below our estimate of [[fair value]] ($35.06)

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is less than 20% higher than the current share price.

Kenvue (NYSE:KVUE) - Aandelenkoers, Nieuws & Analyse

KVUE Overzicht aandelen

Kenvue Inc. is een bedrijf dat wereldwijd actief is op het gebied van consumentengezondheid.

Over het bedrijf

KVUE fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	3/6
Prestaties in het verleden	1/6
Financiële gezondheid	2/6
Dividenden	2/6

Beloningen

Trading at 35.2% below our estimate of its fair value

Earnings are forecast to grow 17.56% per year

Risicoanalyse

Has a high level of debt

Large one-off items impacting financial results

Profit margins (7.2%) are lower than last year (12%)

Dividend of 3.61% is not well covered by earnings

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Critical Brand Investments And Operational Efficiencies Set To Spur Robust Growth And Investor Confidence

Key Takeaways Strategic investments in brand marketing and launching new products like Tylenol Easy To Swallow aim at enhancing market penetration and consumer loyalty. Initiatives such as the Vue Forward program and product innovation, including endorsements by health professionals, are poised to positively impact net margins and revenue growth.

View narrative

US$23.99

5.2% undervalued

4.35%

Revenue growth p.a.

5 days ago

julio

Community Contributor

J&J spinoff

Bulls With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business. Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue ’ s brands.

View narrative

US$25.09

9.4% undervalued

8.70%

Revenue growth p.a.

7 days ago

Kenvue Inc. Concurrenten

Estée Lauder Companies

NYSE:EL

US$23.9b

BellRing Brands

NYSE:BRBR

US$8.6b

Coty

NYSE:COTY

US$6.5b

e.l.f. Beauty

NYSE:ELF

US$5.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Kenvue
Historische aandelenkoersen
Huidige aandelenkoers	US$22.73
52 Week Hoogtepunt	US$23.55
52 Week Laag	US$17.67
Bèta	0
11 maand verandering	2.57%
3 maanden verandering	8.96%
1 Jaar Verandering	17.47%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-15.50%

Recent nieuws en updates

Kenvue: Unpacking Activist's Case And Earnings Preview

Oct 29

Kenvue (NYSE:KVUE) Has Affirmed Its Dividend Of $0.205

Oct 22

Recent updates

Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business

Oct 02

Kenvue (NYSE:KVUE) Has A Pretty Healthy Balance Sheet

Sep 08

Kenvue: Promising Steps Toward Long-Term Success

Aug 11

Kenvue Is A Premier Consumer Company, But I Am Waiting For A Lower Price Before I Buy

Aug 02

Is There An Opportunity With Kenvue Inc.'s (NYSE:KVUE) 36% Undervaluation?

Jul 15

Kenvue: A 4% Yield Worth Going Long

Jun 12

Kenvue's (NYSE:KVUE) Soft Earnings Don't Show The Whole Picture

May 21

Kenvue Q1 Earnings Preview: A Potentially Troubling Trend

May 03

Kenvue: Fairly Valued Spinout

Apr 17

Is Kenvue Inc. (NYSE:KVUE) Trading At A 31% Discount?

Apr 08

Kenvue: This Dividend Newcomer Is Worth A Look

Feb 13

Kenvue: What To Expect From Its First Full-Year Report As A Standalone Company

Feb 05

Kenvue: Portfolio Filled Of Market Leaders

Dec 20

Kenvue Inc.'s (NYSE:KVUE) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 07

Kenvue: Dude, Where's My Dividend Growth?

Nov 26

Kenvue: Only A Watchlist Stock For Now

Nov 19

There May Be Some Bright Spots In Kenvue's (NYSE:KVUE) Earnings

Nov 10

Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond

Oct 19

Kenvue: Interesting Times

Sep 18

Kenvue: Charting A Healthy Future In Consumer Health

Sep 06

Kenvue Split-Off: Still Undecided? 3 (And A Half) Aspects To Consider

Aug 16

Kenvue: A Buffett-Style Investment At A Reasonable Price

Jul 11

Johnson & Johnson Spinoff Kenvue Is Worth Owning - But Maybe Not Yet

Jun 13

Rendement voor aandeelhouders

	KVUE	US Personal Products	US Markt
7D	-0.7%	-8.3%	-1.6%
1Y	17.5%	-10.5%	30.8%

Rendement versus industrie: KVUE exceeded the US Personal Products industry which returned -10.5% over the past year.

Rendement versus markt: KVUE underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is KVUE's price volatile compared to industry and market?
KVUE volatility
KVUE Average Weekly Movement	4.9%
Personal Products Industry Average Movement	7.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: KVUE has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: KVUE's weekly volatility (5%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2022	22,000	Thibaut Mongon	www.kenvue.com

Kenvue Inc. is een bedrijf dat wereldwijd actief is op het gebied van consumentengezondheid. Het bedrijf is actief in drie segmenten: Zelfzorg, Huidgezondheid en Schoonheid, en Essentiële Gezondheid. Het segment Zelfzorg biedt hoest, verkoudheid en allergie, pijnbestrijding, spijsvertering, stoppen met roken, oogverzorging en andere producten onder de merknamen Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol en Zyrtec.

Kenvue Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Kenvue zich tot de beurswaarde?
KVUE fundamentele statistieken
Marktkapitalisatie	US$43.53b
Inkomsten(TTM)	US$1.12b
Inkomsten(TTM)	US$15.48b

38.9x

Koers/Winstverhouding

2.8x

P/S-verhouding

Is KVUE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
KVUE resultatenrekening (TTM)
Inkomsten	US$15.48b
Kosten van inkomsten	US$6.58b
Brutowinst	US$8.90b
Overige uitgaven	US$7.78b
Inkomsten	US$1.12b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	0.58
Brutomarge	57.51%
Nettowinstmarge	7.23%
Schuld/Eigen Vermogen Verhouding	82.2%

Hoe presteerde KVUE op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.6%

Huidig dividendrendement

137%

Uitbetalingsratio

Betaalt KVUE een betrouwbaar dividend?

Zie KVUE dividendgeschiedenis en benchmarks

Wanneer moet je KVUE kopen om een aanstaand dividend te ontvangen?
Kenvue dividenddata
Ex Dividend Datum	Nov 13 2024
Betaaldatum dividend	Nov 27 2024
Dagen tot Ex-dividend	9 days
Dagen tot dividendbetaaldatum	23 days

Betaalt KVUE een betrouwbaar dividend?

Zie KVUE dividendgeschiedenis en benchmarks

KVUE Overzicht aandelen

Beloningen

Risicoanalyse

Critical Brand Investments And Operational Efficiencies Set To Spur Robust Growth And Investor Confidence

J&J spinoff

Kenvue Inc. Concurrenten

NYSE:EL

US$23.9b

NYSE:BRBR

US$8.6b

NYSE:COTY

US$6.5b

NYSE:ELF

US$5.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Kenvue: Unpacking Activist's Case And Earnings Preview

Starboard Value Sets its Sights on Kenvue

Kenvue (NYSE:KVUE) Has Affirmed Its Dividend Of $0.205

Starboard Value Sets its Sights on Kenvue

Second quarter dividend of US$0.20 announced

Kenvue Inc. to Report Q3, 2024 Results on Nov 07, 2024

Recent updates

Kenvue: Unpacking Activist's Case And Earnings Preview

Starboard Value Sets its Sights on Kenvue

Kenvue (NYSE:KVUE) Has Affirmed Its Dividend Of $0.205

Starboard Value Sets its Sights on Kenvue

Second quarter dividend of US$0.20 announced

Kenvue Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kenvue Declares Quarterly Cash Dividend, Payable on November 27, 2024

Investors Met With Slowing Returns on Capital At Kenvue (NYSE:KVUE)

Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business

Kenvue (NYSE:KVUE) Has A Pretty Healthy Balance Sheet

Kenvue Inc. Introduces Patented Micro-Peptide Technology with Neutrogena Collagen Bank Launch

Kenvue: Promising Steps Toward Long-Term Success

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Kenvue Inc. Re-Affirms Earnings Guidance for the Year 2024

Kenvue Is A Premier Consumer Company, But I Am Waiting For A Lower Price Before I Buy

Kenvue Inc. Announces Board Changes

First quarter dividend increased to US$0.20

Kenvue Increases Quarterly Cash Dividend, Payable on August 28, 2024

Is There An Opportunity With Kenvue Inc.'s (NYSE:KVUE) 36% Undervaluation?

Kenvue Inc. to Report Q2, 2024 Results on Aug 06, 2024

Kenvue: A 4% Yield Worth Going Long

Kenvue's (NYSE:KVUE) Soft Earnings Don't Show The Whole Picture

Kenvue Inc. has completed a Follow-on Equity Offering in the amount of $3.646591 billion.

Kenvue Inc. has filed a Follow-on Equity Offering.

Kenvue Inc. has filed a Follow-on Equity Offering.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Kenvue Inc. Re-Affirms Earnings Guidance for the Year 2024

Kenvue Q1 Earnings Preview: A Potentially Troubling Trend

Upcoming dividend of US$0.20 per share

Kenvue Declares Quarterly Cash Dividend, Payable on May 22, 2024

Kenvue: Fairly Valued Spinout

Kenvue Inc., Annual General Meeting, May 23, 2024

Is Kenvue Inc. (NYSE:KVUE) Trading At A 31% Discount?

Kenvue Inc. to Report Q1, 2024 Results on May 07, 2024

CEO & Director exercised options and sold US$1.9m worth of stock

Kenvue: This Dividend Newcomer Is Worth A Look

Full year 2023 earnings: EPS misses analyst expectations

Kenvue Inc. Provides Earnings Guidance for the Year 2024

Upcoming dividend of US$0.20 per share at 3.9% yield

Kenvue: What To Expect From Its First Full-Year Report As A Standalone Company

Kenvue Inc. Announces Quarterly Cash Dividend, Payable on February 28, 2024

Kenvue Inc. to Report Q4, 2023 Results on Feb 08, 2024

Kenvue: Portfolio Filled Of Market Leaders

Kenvue Inc. Announces Transition of Kathleen Widmer as Group President, North America and Latin America, Effective on December 31, 2023

Kenvue Inc.'s (NYSE:KVUE) Intrinsic Value Is Potentially 42% Above Its Share Price

Kenvue Inc. Announces Transition of Kathleen Widmer as Group President, North America and Latin America, Effective on December 31, 2023

Kenvue: Dude, Where's My Dividend Growth?

Kenvue: Only A Watchlist Stock For Now

The Law Offices of Vincent Wong Commences Class Action Lawsuit Against Kenvue Inc

There May Be Some Bright Spots In Kenvue's (NYSE:KVUE) Earnings

Upcoming dividend of US$0.20 per share at 4.3% yield

Kenvue Inc. Declares Quarterly Cash Dividend, Payable on November 22, 2023

Kenvue Inc. Provides Earnings Outlook for the Fiscal 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Kenvue: Consumer Health Giant's Journey From IPO To Legal Challenges And Beyond

The Portnoy Law Firm Files Lawsuit Against Kenvue Inc

Kenvue Inc. to Report Q3, 2023 Results on Oct 26, 2023